ORIGINAL ARTICLE

Nursing-home-acquired pneumonia in Germany: an 8-year prospective multicentre study

Santiago Ewig,¹ Benjamin Klapdor,¹ Mathias W Pletz,² Gernot Rohde,³ Hartwig Schütte,⁴ Tom Schaberg,⁵ Torsten T Bauer,⁶ Tobias Welte,⁷ for the CAPNETZ study group

¹Thoraxzentrum Ruhrgebiet, Department of Respiratory and Infectious Diseases, EVK Herne and Augusta-Kranken-Anstalt Bochum, Germany

²Division of Gastroenterology, Hepatology and Infectious Diseases, Jena University Hospital, Jena, Germany

³Department of Respiratory Medicine, Maastricht University Medical Centre, The Netherlands

⁴Medical Clinic, Infectious Diseases and Respiratory Medicine, Charité — Berlin University, Berlin, Germany

⁵Diakoniekrankenhaus, Respiratory Clinic Unterstedt, Rotenburg an der Wümme, Germany

⁶Lungenklinik Heckeshorn, Helios Klinikum Emil von Behring, Berlin, Germany

⁷Department of Respiratory Medicine, Hannover University, Hannover, Germany

Correspondence to

Prof Santiago Ewig, Thoraxzentrum Ruhrgebiet, Kliniken für Pneumologie und Infektiologie, EVK Herne und Augusta-Kranken-Anstalt Bochum, Bergstrasse 26, 44791 Bochum, Germany; sewig@versanet.de

Received 16 June 2011

Accepted 13 October 2011

Published Online First

5 November 2011

ABSTRACT

Objective To determine differences in aetiologies, initial antimicrobial treatment choices and outcomes in patients with nursing-home-acquired pneumonia (NHAP) compared with patients with community-acquired pneumonia (CAP), which is a controversial issue.

Methods Data from the prospective multicentre Competence Network for Community-acquired pneumonia (CAPNETZ) database were analysed for hospitalised patients aged ≥ 65 years with CAP or NHAP. Potential differences in baseline characteristics, comorbidities, physical examination findings, severity at presentation, initial laboratory investigations, blood gases, microbial investigations, aetiologies, antimicrobial treatment and outcomes were determined between the two groups.

Results Patients with NHAP presented with more severe pneumonia as assessed by CRB-65 (confusion, respiratory rate, blood pressure, 65 years and older) score than patients with CAP but received the same frequency of mechanical ventilation and less antimicrobial combination treatment. There were no clinically relevant differences in aetiology, with *Streptococcus pneumoniae* the most important pathogen in both groups, and potential multidrug-resistant pathogens were very rare ($<5\%$). Only *Staphylococcus aureus* was more frequent in the NHAP group ($n=12$, 2.3% of the total population, 3.1% of those with microbial sampling compared with 0.7% and 0.8% in the CAP group, respectively). Short-term and long-term mortality in the NHAP group was higher than in the CAP group for patients aged ≥ 65 years (26.6% vs 7.2% and 43.8% vs 14.6%, respectively). However, there was no association between excess mortality and potential multidrug-resistant pathogens.

Conclusions Excess mortality in patients with NHAP cannot be attributed to a different microbial pattern but appears to result from increased comorbidities, and consequently, pneumonia is frequently considered and managed as a terminal event.

INTRODUCTION

The epidemiology of community-acquired pneumonia (CAP) has undergone significant changes in the past few decades. Patients with CAP present at an increasingly older age and with severe disabilities. Mortality in these patients is usually high, reaching up to 30%.^{1 2}

As a consequence, CAP ‘in the elderly’^{3–8} and ‘in the very elderly’⁹ has attracted considerable interest in the investigation of the disease. In particular,

Key messages

What is the key question?

- ▶ Nursing-home-acquired pneumonia (NHAP) is associated with considerably higher mortality than community-acquired pneumonia (CAP).
- ▶ Whether this higher mortality rate is related to different aetiologies including potential multidrug resistant (MDR) pathogens and consequently inadequate initial antimicrobial coverage remains a controversial issue.

What is the bottom line?

- ▶ NHAP does not differ from CAP in terms of aetiology and excess mortality is not related to the inadequate treatment of potential MDR pathogens.
- ▶ Excess mortality results from higher comorbidities and pneumonia frequently being considered and managed as a terminal event of advanced age and poor functional status.

Why read on?

- ▶ NHAP is a frequent condition.
- ▶ Understanding the reasons for excess mortality will allow adequate management of these patients.

patients living in nursing homes were identified as those with the highest mortality.^{1 10–12} Data from the USA indicate an excess of multidrug resistant (MDR) pathogens in patients with chronic healthcare contacts, and patients with ‘nursing-home-acquired pneumonia’ (NHAP) were included under the concept of ‘healthcare-associated pneumonia’ (HCAP).^{13 14}

The HCAP concept has been subject to criticism. Whereas there is no doubt that older patients and those with disabilities have an increased mortality, the main hypothesis that MDR pathogens account for this excess mortality remains unproven. Moreover, leading criteria for HCAP, including severe immunosuppression and recent hospitalisation, remain questionable. Patients with severe immunosuppression form a distinct group and should not be included under the concept of HCAP. Recently hospitalised patients are clearly at risk from MDR pathogens but should be regarded and managed as patients with nosocomial pneumonia.¹⁵ If this

rearrangement is accepted, the only remaining core group of HCAP is NHAP.¹⁶

We therefore investigated the clinical characteristics, microbial patterns and outcomes of patients with NHAP included on the large prospective Competence Network for Community-acquired pneumonia (CAPNETZ) database. In particular, we examined the association between aetiology and in-hospital mortality. Recently, we showed that there are fundamental differences in aetiology and outcome in younger patients with CAP compared with those aged ≥ 65 years; in fact, it is a completely separate entity.¹⁷ In view of these data, we thought it most appropriate to compare hospitalised patients with CAP or NHAP aged ≥ 65 years. This would avoid inflation of differences due to the younger patient population.

METHODS

Patients

The methodology of CAPNETZ has been reported elsewhere.¹⁸ Overall, 15 local clinical centres throughout Germany were involved. Prospective patients were those aged ≥ 18 years with a pulmonary infiltrate diagnosed by chest x-ray, clinical symptoms of fever, cough, purulent sputum or positive auscultation. Exclusion criteria were age < 18 years, acquired or therapeutically induced immune deficiency, active tuberculosis or a possible nosocomial genesis of infection (hospitalisation < 4 weeks prior to infection). Cases were reported to the local participating clinical centre via a network of sentinel practices and hospitals.

The study was approved by the central and local ethics committees and written informed consent was obtained from all patients.

Data collection

Demographic, clinical, and diagnostic data were recorded using standardised web-based data sheets. The study period was 90 months from January 2002 to June 2009.

Microbial investigation

The methods applied have been described previously.¹⁸ Briefly, samples obtained included sputum and/or other respiratory secretions, blood cultures, urinary antigen testing for *Streptococcus pneumoniae* and *Legionella pneumophila* serogroup 1, serology, and nasal and pharyngeal swabs. Investigations for *Mycoplasma pneumoniae* were performed as described in a previous report.¹⁹ Investigations for viruses were only carried out until July 2007. All samples were immediately processed in the local participating microbiological laboratories according to the German Quality Standards in Clinical Microbiology and Infectious Diseases.²⁰

To limit possible bias due to incomplete sampling and limited diagnostic yield of microbial investigation, pathogen frequencies were reported using the following denominators: total population; cases with microbial sampling (including those techniques able to detect the pathogen in question); cases with a pathogen determined.

Susceptibility testing was not generally recorded, with the exception of *Staphylococcus aureus*. Therefore, all enterobacteriaceae, *Pseudomonas aeruginosa* and *S aureus* isolates were considered to be potential MDR pathogens.

CRB-65 score and mortality

The CRB-65 score consists of four variables: confusion, respiratory rate ≥ 30 /min, systolic blood pressure < 90 mm Hg or diastolic blood pressure ≤ 60 mm Hg, and age ≥ 65 years. One

point is given for each parameter present, which results in CRB-65 scores of 0–4. For each patient the CRB-65 score was calculated with patient data assessed at first presentation.

Short-term mortality was defined as death within 30 days of diagnosis and long-term mortality as death within 180 days of diagnosis.

Statistical analysis

Hospitalised patients aged ≥ 65 years with CAP were considered to represent the current standard group and were compared with patients aged ≥ 65 years with NHAP.

Comparisons between groups were performed by means of the χ^2 test for categorical variables and the Student t test for continuous variables (or the non-parametric Mann–Whitney U test when data were not normally distributed). All analyses were performed using SPSS software (SPSS 19.0; SPSS Inc., Chicago, IL, USA). All tests of significance were two tailed and α was set at 0.05.

RESULTS

Patient population

Overall, 3087 hospitalised patients aged ≥ 65 years were included in our analysis. Of these, 518 had NHAP.

Baseline characteristics

The following characteristics were significantly different: the NHAP group consisted of more women, had lower body mass index and fewer cases of obesity, were less frequent smokers and less frequently on long-term oxygen treatment (table 1).

Table 1 Baseline characteristics and comorbidities

Variable	Patients with CAP ≥ 65 years (n = 2569)	Patients with NHAP ≥ 65 years (n = 518)	p Value
Age, years (median (IQR) (n))	76.1 (10.8) (2569)	83.3 (12.0) (518)	< 0.001
Men, n (%)	1609 (62.6)	221 (42.7)	< 0.001
Weight, kg (median (IQR) (n))	74 (20) (2488)	65 (19) (423)	< 0.001
Height, cm (median (IQR) (n))	170 (13) (2483)	167 (12) (426)	< 0.001
BMI, kg/m ² (median (IQR) (n))	25.2 (5.7) (2480)	23.0 (5.0) (420)	< 0.001
Obesity (BMI ≥ 30), n (%)	433 (17.5)	31 (7.4)	< 0.001
Smoker, n (%)	453 (18.3)	40 (8.9)	< 0.001
Pack-years (median (IQR) (n))	30 (35) (1095)	30 (28) (78)	0.285
Long-term oxygen therapy, n (%)	209 (8.2)	16 (3.1)	< 0.001
Pneumococcal vaccination in the past 5 years, n (%)	389 (17.1)	27 (9.3)	< 0.001
Comorbidity, n (%)	2275 (90.2)	376 (97.1)	< 0.001
Chronic respiratory disease	1197 (46.8)	153 (30.3)	< 0.001
Congestive heart failure	901 (35.2)	265 (52.1)	< 0.001
Other heart diseases	1376 (54.0)	258 (51.0)	0.221
Cerebrovascular disease	390 (15.2)	336 (66.1)	< 0.001
Other chronic neurological disorder	203 (7.9)	152 (29.9)	< 0.001
Renal insufficiency	419 (16.4)	121 (24.0)	< 0.001
Chronic liver disease	83 (3.2)	14 (2.8)	0.575
Diabetes mellitus	726 (28.3)	170 (33.3)	0.022
Malignancy	371 (14.5)	58 (11.6)	0.088

BMI, body mass index; CAP, community-acquired pneumonia; NHAP, nursing-home-acquired pneumonia.

Comorbidities

Comorbidity was very common in both groups but even more so in patients with NHAP (97.1% vs 90.2%). Chronic respiratory disease was less frequent whereas congestive heart failure, cerebrovascular diseases, renal diseases and diabetes mellitus were more frequent in patients with NHAP. The largest difference was in patients with cerebrovascular disease (66.1% vs 15.2% for the NHAP and CAP groups, respectively) (table 1).

Physical examination findings

Cough, sputum expectoration and chest pain were less common, whereas confusion, low blood pressure and tachypnoea were more common in the NHAP group compared with the CAP group, indicating more severe pneumonia at presentation (table 2).

Laboratory investigations

The main differences related to a higher frequency of anaemia and leucocytosis, and to a higher thrombocyte count in the NHAP group. However, mean C-reactive protein (CRP) was lower (table 2).

Table 2 Initial physical examination and laboratory findings

Variable	Patients with CAP≥65 years (n=2569)	Patients with NHAP≥65 years (n=518)	p Value
Cough, n (%)	2266 (88.5)	425 (83.3)	0.001
Purulent sputum, n (%)	1394 (54.5)	210 (41.3)	<0.001
Fever, n (%)	1461 (56.9)	294 (56.8)	0.955
Dyspnoea, n (%)	2072 (81.2)	424 (84.1)	0.123
Confusion, n (%)	374 (14.7)	243 (49.2)	<0.001
Chest pain, n (%)	820 (33.2)	65 (16.4)	<0.001
Severe hypotension*, n (%)	542 (21.2)	154 (30.3)	<0.001
Tachycardia†, n (%)	885 (34.7)	197 (38.6)	0.091
Tachypnea‡, n (%)	310 (13.0)	83 (17.8)	0.007
Haemoglobin, g/dl (median (IQR) (n))	13.2 (2.4) (2508)	12.6 (2.7) (507)	<0.001
Anaemia§, n (%)	892 (35.6)	225 (44.4)	<0.001
Complete blood count, n (%)	2535 (99.7)	508 (99.8)	0.751
With differential, n (%)	716 (29.1)	110 (22.6)	0.004
Haematocrit, % (median (IQR) (n))	39.0 (6.0) (2327)	38.0 (7.0) (474)	<0.001
Platelets, /10 ⁻⁹ litre (median (IQR) (n))	230 (123) (2491)	259 (143) (502)	<0.001
Thrombopenia¶, n (%)	243 (9.8)	33 (6.6)	0.025
Leucocytes, /10 ⁻⁹ litre (median (IQR) (n))	12.4 (7.1) (2532)	13.5 (8.5) (507)	0.001
Leucocytosis**, n (%)	46 (1.8)	13 (2.6)	0.266
Leucopenia††, n (%)	33 (1.3)	6 (1.2)	0.827
Lymphocytes, % (median (IQR) (n))	10 (9) (710)	8.5 (8.4) (109)	0.392
CRP, mg/litre (median (IQR) (n))	112 (180) (2478)	97 (149) (492)	0.023
BUN, mg/dl (median (IQR) (n))	20.2 (15.5) (2163)	24.9 (23.9) (454)	<0.001

*Systolic <90 mm Hg or diastolic ≤60 mm Hg.

†Heart rate >100/min.

‡Respiratory rate ≥30/min.

§12 g/dl for women, 13 g/dl for men.

¶Platelet count <140/10⁻⁹ litre.

**Leucocytes >30/10⁻⁹ litre.

††Leucocytes <4/10⁻⁹ litre.

BUN, blood urea nitrogen; CAP, community-acquired pneumonia; CRP, C-reactive protein; NHAP, nursing-home-acquired pneumonia.

Gas exchange

Arterial blood gas analysis was performed less frequently in patients with NHAP compared with those with CAP (69.9% vs 78.1%, $p<0.001$).

Severity at presentation

The time from symptom presentation to hospital attendance was around 2 days less in the NHAP group compared with the CAP group. The proportion of patients classified as CRB-65 3–4 was around threefold higher in the NHAP group. However, the rate of mechanical ventilation was similar (5.0% vs 4.8%) (table 3).

Microbial aetiology

Diagnostic samples (package 1: blood cultures and urine antigen testing, $n=1938$ (80.4%) vs $n=265$ (63.5%), $p<0.001$; package 2: blood cultures and urine antigen testing plus respiratory sample, $n=933$ (38.7%) vs $n=49$ (11.8%), $p<0.001$) were retrieved less frequently in the NHAP group compared with the CAP group.

The proportion of patients with a diagnostic investigation able to identify a potential MDR pathogen (methicillin-resistant *S aureus* (MRSA), enterobacteria, *P aeruginosa*) was significantly lower in the NHAP group ($n=2350$ vs $n=382$, 91.4% vs 73.7%, $p<0.001$).

The overall findings for microbial investigation were similar (27.7% vs 29.7%). *S pneumoniae* was the most frequent pathogen in both groups. Potential MDR pathogens such as enterobacteriaceae, *P aeruginosa* and *S aureus* were all very rare (<5% for the total population and for patients with microbial sampling). There were only minor differences in pathogens, with *H influenzae* and *M pneumoniae* being less frequent and *S aureus* more frequent in patients with NHAP. In the NHAP group, 11 of 12 patients with *S aureus* had central nervous system (CNS) disorders. However, the absolute and relative frequency of *S aureus* was minimal ($n=12$, 2.3% of total population, 3.1% of those with microbial sampling and 10.3% of those with a pathogen determined), and of these, only two cases were MRSA (table 4).

Antimicrobial treatment

Patients with NHAP received antimicrobial pretreatment less frequently than patients with CAP (14.5% vs 18.9%). Monotherapy was more frequent and combination treatment less frequent in patients with NHAP (22.8% vs 41.8% and 77.2% vs 57.2%). In addition, more patients with NHAP received β -lactams and fewer received macrolides (91.6% vs 86.9% and 16.6% vs 38.4%) and a change in antimicrobial treatment was

Table 3 Severity of pneumonia at admission

Variable	Patients with CAP≥65 years (n=2569)	Patients with NHAP≥65 years (n=518)	p Value
Mechanical ventilation, n (%)	123 (4.8)	26 (5.0)	0.815
CRB-65 score, n (%)			
0	0	0	—
1–2	2165 (92.3)	327 (73.3)	<0.001
3–4	181 (7.7)	119 (26.7)	<0.001
Time from symptoms until presentation, days (median (IQR) (n))	4 (5) (1513)	2 (4) (226)	<0.001
Length of stay, days (median (IQR) (n))	11 (7) (2429)	10 (7) (436)	<0.001

CAP, community-acquired pneumonia; CRB-65, confusion, respiratory rate, blood pressure, 65 years and older; NHAP, nursing-home-acquired pneumonia.

Table 4 Aetiology of pneumonia

Variable	Total population			Cases with microbial sampling			Cases with a pathogen determined		
	Patients with CAP $\geq$ 65 years (n = 2569)	Patients with NHAP $\geq$ 65 years (n = 518)	p Value	Patients with CAP $\geq$ 65 years (n = 2569)	Patients with NHAP $\geq$ 65 years (n = 518)	p Value	Patients with CAP $\geq$ 65 years (n = 2569)	Patients with NHAP $\geq$ 65 years (n = 518)	p Value
<i>Streptococcus pneumoniae</i> , n (%)	259/2569 (10.1)	38/518 (7.3)	0.053	259/2413 (10.7)	38/417 (9.1)	0.319	259/721 (35.9)	38/117 (32.5)	0.470
<i>Mycoplasma pneumoniae</i> , n (%)	35/2569 (1.4)	1/518 (0.2)	0.024	35/2065 (1.7)	1/330 (0.3)	0.054	35/721 (4.8)	1/117 (0.9)	0.052
<i>Legionella</i> spp., n (%)	102/2569 (4.0)	13/518 (2.5)	0.109	102/2243 (4.5)	13/357 (3.6)	0.439	102/721 (14.1)	13/117 (11.1)	0.376
<i>Haemophilus influenzae</i> , n (%)	30/2569 (1.2)	1/518 (0.2)	0.042	30/2350 (1.3)	1/382 (0.3)	0.082	30/721 (4.2)	1/117 (0.9)	0.079
Enterobacteria, n (%)	67/2569 (2.6)	17/518 (3.3)	0.390	67/2350 (2.9)	17/382 (4.5)	0.093	67/721 (9.3)	17/117 (14.5)	0.080
<i>Pseudomonas aeruginosa</i> , n (%)	23/2569 (0.9)	4/518 (0.8)	0.784	23/2350 (1.0)	4/382 (1.0)	0.900	23/721 (3.2)	4/117 (3.4)	0.837
<i>Staphylococcus aureus</i> *, n (%)	18/2569 (0.7)	12/518 (2.3)	0.001	18/2350 (0.8)	12/382 (3.1)	73.1 <0.001	18/721 (2.5)	12/117 (10.3)	<0.001
<i>Moraxella catarrhalis</i> , n (%)	9/2569 (0.4)	1/518 (0.2)	0.566	9/2350 (0.4)	1/382 (0.3)	0.716	9/721 (1.2)	1/117 (0.9)	0.716
Influenza A, n (%)	59/2569 (2.3)	9/518 (1.7)	0.429	59/1786 (3.3)	9/312 (2.9)	0.700	59/721 (8.2)	9/117 (7.7)	0.857
Other pathogens, n (%)†	57/2569 (2.2)	11/518 (2.1)	0.893						

Aetiology is presented as pathogens per total population; pathogens per patients with microbial sampling; pathogens per patients with a pathogen determined. Enterobacteria comprise: *Escherichia coli*, *Klebsiella pneumoniae*, *Klebsiella oxytoca*, *Enterobacter* spp., *Proteus mirabilis*, *Serratia marcescens*, *Citrobacter* spp., *Morganella morganii*.

*n=2 accounted for methicillin-resistant *S. aureus*.

†Undetermined as aetiology.

CAP, community-acquired pneumonia; NHAP, nursing-home-acquired pneumonia.

performed more frequently in patients with NHAP (42.4% vs 36.6%) (table 5).

Outcomes

Short-term mortality was nearly fourfold higher in the NHAP group compared with the CAP group (26.6 vs 7.2%), and long-term mortality nearly threefold higher (43.8% vs 14.6%) (table 5).

Table 5 Initial antimicrobial treatment and outcomes

Variable	Patients with CAP $\geq$ 65 years (n = 2569)	Patients with NHAP $\geq$ 65 years (n = 518)	p Value
Prior antibiotic therapy*, n (%)	481 (18.9)	73 (14.5)	0.019
Initial antibiotic therapy, n (%)	2550 (99.3)	513 (99.0)	0.523
Monotherapy, n (%)	1476 (57.9)	396 (77.2)	<0.001
Combination, n (%)	1067 (41.8)	117 (22.8)	<0.001
Duration of antibiotic therapy, days (median (IQR) (n))	10 (6) (2342)	10 (6) (400)	<0.001
Change in antibiotic therapy, n (%)	876 (36.6)	176 (42.4)	0.023
β -Lactam antibiotics, n (%)	2216 (86.9)	470 (91.6)	0.003
Penicillins, n (%)	1258 (49.3)	280 (54.6)	0.030
Cephalosporins, n (%)	941 (36.9)	193 (37.6)	0.758
Carbapenems, n (%)	29 (1.1)	5 (1.0)	0.748
Macrolides, n (%)	980 (38.4)	85 (16.6)	<0.001
Quinolones, n (%)	358 (14.0)	54 (10.5)	0.033
Tetracyclines, n (%)	9 (0.4)	0 (0.0)	0.178
Glycopeptides, n (%)	6 (0.2)	0 (0.0)	0.271
Lincosamides, n (%)	15 (0.6)	4 (0.8)	0.614
Ketolides, n (%)	1 (0.0)	0 (0.0)	0.654
co-Trimoxazole, n (%)	6 (0.2)	2 (0.4)	0.531
Aminoglycosides, n (%)	8 (0.3)	4 (0.8)	0.123
Other antibiotics, n (%)	11 (0.4)	10 (1.9)	<0.001
Died within 30 days, n (%)	172 (7.2)	105 (26.6)	<0.001
Died within 180 days, n (%)	352 (14.6)	173 (43.8)	<0.001

*Antibiotic therapy during the last 4 weeks.

CAP, community-acquired pneumonia; NHAP, nursing-home-acquired pneumonia.

Death rates were still very high in patients with NHAP without comorbidities, reaching 23.1% vs 2.6% for short-term mortality and 30.8% vs 6.8% for long-term mortality.

Patients receiving enteral tube feeding (n=103, 78.6% in the NHAP group) had the highest mortality rates (30.7% short-term and 56% long-term mortality).

Mortality rates according to aetiology in both groups are listed in table 6. Short-term mortality in patients with CAP aged $\geq$ 65 years was between 3.4% and 12.5%, with the highest rates for *S. aureus*, enterobacteriaceae, *P. aeruginosa* and influenza A whereas it was threefold to fourfold higher for all leading pathogens in patients with NHAP. Similar rates were obvious in long-term mortality, with *S. aureus* being associated with an extremely high mortality rate (80%).

DISCUSSION

The most important findings of this study were the following: patients with NHAP presented with more severe pneumonia but received the same frequency of mechanical ventilation and less antimicrobial combination treatment; there were no clinically relevant differences in aetiology and potential MDR pathogens were very rare (<5%); short-term and long-term mortality for NHAP was about fourfold and threefold higher than for CAP in patients aged $\geq$ 65 years, however excess mortality was a general pattern and not related to MDR pathogens.

Our approach to limit the comparison of patients to those aged $\geq$ 65 years is an important methodological decision. In a previous study from the CAPNETZ group comparing patients aged <65 years and $\geq$ 65 years, those with NHAP showed a fourfold increased mortality rate and an increased rate of gram-negative bacillary infections compared with patients living in the community (7.1% vs 3.7%, expressed as rate of pathogens per cases with pathogens identified).²¹ This difference, however, is mainly a result of inflation by including a significant number of younger patients. In view of the fundamentally different epidemiology and prognosis of patients <65 years,¹⁸ we argue that the characteristics of NHAP can be assessed more

Table 6 Short-term and long-term mortality according to underlying aetiologies

Pathogen	Short-term mortality		p Value	Long-term mortality		p Value
	Patients with CAP $\geq$ 65 years (n=2569)	Patients with NHAP $\geq$ 65 years (n=518)		Patients with CAP $\geq$ 65 years (n=2569)	Patients with NHAP $\geq$ 65 years (n=518)	
<i>Streptococcus pneumoniae</i> , n (%)	17/244 (7.0)	8/29 (27.6)	<0.001	99/244 (11.9)	10/29 (34.5)	0.001
<i>Mycoplasma pneumoniae</i> , n (%)	2/34 (5.9)	0/0	NC	5/34 (14.7)	0/0	NC
<i>Legionella</i> spp., n (%)	5/95 (5.3)	2/12 (16.7)	0.132	13/95 (13.7)	4/12 (33.3)	0.079
<i>Haemophilus influenzae</i> , n (%)	1/29 (3.4)	0/1 (0.0)	0.850	1/29 (3.4)	0/1 (0.0)	0.850
Enterobacteriaceae, n (%)	7/67 (10.4)	4/11 (36.4)	0.022	11/67 (16.4)	5/11 (45.5)	0.027
<i>Pseudomonas</i> spp., n (%)	2/22 (9.1)	1/3 (33.3)	0.225	2/22 (9.1)	1/3 (33.3)	0.225
<i>Staphylococcus aureus</i> *, n (%)	2/17 (11.8)	4/10 (40.0)	0.088	6/17 (35.3)	8/10 (80.0)	0.025
<i>Moraxella catarrhalis</i> , n (%)	1/8 (12.5)	0/1 (0.0)	0.708	2/8 (25.0)	1/1 (100.0)	0.134
Influenza A, n (%)	5/55 (9.1)	1/8 (12.5)	0.759	6/55 (10.9)	2/8 (25.0)	0.263

*n=1 accounted for methicillin-resistant *S. aureus*.

CAP, community-acquired pneumonia; NC, not calculable; NHAP, nursing-home-acquired pneumonia.

effectively by restricting the comparator to patients with CAP aged ≥ 65 years. To avoid the impact of age, patients with NHAP were also restricted to those aged ≥ 65 years.

Patients with NHAP were a clinically distinct group compared with those aged ≥ 65 years. They had a mean age of over 80 years, more frequently had congestive heart failure, cerebrovascular disease, renal disease and diabetes mellitus, indicating that cardiovascular and neurological morbidity was the primary underlying condition. Although these patients presented more quickly after developing symptoms, initial pneumonia severity was clearly higher according to symptoms at presentation and CRB-65 scoring. Nevertheless, they obviously received less attention and initial antimicrobial treatment was not as intensive: blood gas analysis was performed around 10% less frequently and antimicrobial combination treatment was administered in only half of cases compared with patients without NHAP. In addition, despite higher severity according to CRB-65 scoring and the presence of severe hypotension, mechanical ventilation was not given more frequently. However, short-term and long-term mortality was far higher. All these observations clearly show treatment restrictions due to advanced age and severe disabling conditions in a significant number of patients with NHAP. Unfortunately, we did not record data on 'do not resuscitate' (DNR) orders. However, although DNR orders are one form of treatment restriction, other hidden restrictions (such as 'do not re-evaluate extensively in case of treatment failure', 'do not transfer to ICU [intensive care unit]', 'do not ventilate' etc) are usually not recorded. Therefore, we argue that even recording DNR orders actually underestimates the rate of treatment restrictions. We could not identify clinically relevant differences in aetiological patterns or a clinically relevant higher frequency of potential MDR pathogens. In addition, mortality rates according to pathogens clearly show that there is a threefold to fourfold higher mortality for NHAP across all leading pathogens. This is strong evidence against the hypothesis that excess mortality is related to inadequate treatment because of potential MDR pathogens not covered by empirical treatment for CAP. Instead, as described by others, MDR pathogens might be associated with severe disability.²² Thus, the aetiological patterns identified do not account for the short-term and long-term excess mortality observed in patients with NHAP.

We found that most cases of pneumonia caused by *S. aureus* had CNS comorbidity, and that *S. aureus* was associated with the highest mortality. This is explained by the known risk for pneumonia through *S. aureus* in patients with CNS disorders, mainly driven by aspiration.^{23–24} Thus, a careful individual

assessment of risk for specific pathogens is clearly indicated in every patient with NHAP.

For long-term mortality, an interesting observation was a lower mean CRP value in patients with NHAP. Lower CRP values have recently been identified as an independent predictor of long-term mortality. This probably reflects failure to mount a sufficient immune response.²⁵

Our results are in line with two other important European studies. In a British 18-month prospective cohort study of 437 patients admitted to hospital with CAP, 40 (9%) came from nursing homes. Analysis of this small series yielded nearly identical results to our study. Patients with NHAP were less likely to have a productive cough or pleuritic pain but they were more likely to be confused and had more severe disease. In-hospital mortality was extremely high (53% vs 13% in patients with CAP). *S. pneumoniae* was the most common pathogen (55% NHAP, 43% CAP). Atypical pathogens, enterobacteriaceae and *S. aureus* were uncommon. Poor functional status accounted for the increased mortality in NHAP.¹¹ More recently, a Spanish study including 150 consecutive cases of NHAP over a 10-year period showed clinical characteristics comparable to those with hospital-acquired pneumonia. However, microbial patterns and mortality data of patients with NHAP were more similar to those with CAP. Potential MDR pathogens were rare, accounting for only 7% of pathogens.¹² Two recent studies from Spain and the UK on HCAP confirmed this observation for both NHAP and HCAP.^{26–27}

Likewise, the main findings of two Canadian studies were very similar, including comorbidity patterns (more CNS disease, fewer smokers and less pulmonary disease), less *H. influenzae*, high mortality, and differences in treatment (less macrolide treatment).¹⁰ Mortality was very high but functional status rather than different pathogen patterns was the main predictor of death.^{10–28} There was also clear evidence for treatment restrictions.²⁸

Some US data indicate a different microbial pattern in patients with NHAP. For example, El Solh *et al* found 17 of 88 (19%) pathogens of patients with NHAP and severe pneumonia were MDR pathogens²¹; in another study, the authors found anaerobic organisms more often in patients with NHAP and empyema.²⁹ However, this seems to reflect a general trend in older people rather than a specific finding in patients with NHAP. Kaplan *et al* reported extremely high rates of enterobacteriaceae and *P. aeruginosa* in a large population of patients aged ≥ 65 years.² Accordingly, Koeff *et al*¹³ listed exceedingly high rates of MDR pathogens in patients with HCAP (including many with NHAP) but also (to a lesser but still unusually high

extent) in patients with CAP. The latter finding in particular casts doubt on the validity of the microbiological investigation in this study. Finally, it could not be shown that adhering to guideline recommendations for treating patients with HCAP improved outcomes compared with those for CAP.^{30 31}

Taken together, our data and the data reported in the literature so far show that there is no convincing evidence to support generally administering broad spectrum antimicrobial combination treatments comparable to those used for hospital-acquired pneumonia to all patients with NHAP. Instead, the initial antimicrobial coverage may still follow that recommended in CAP guidelines after assessment of specific risk factors for MDR on an individual basis. CNS disorders may particularly be addressed since they predispose people to pneumonia through *S aureus*. Moreover, in patients with NHAP, one cannot overestimate the importance of continuous careful prognostic estimations and ethical decisions on treatment aims and possible restrictions based primarily on patients' preferences.

The strengths of this study include the multicentre prospective design over 8 years, which to the best of our knowledge is unique in the literature. In addition, our population is one of the largest reported in the literature so far. Nevertheless, some potential limitations must be addressed. First, the proportion of patients with an aetiology identified was low and did not exceed 30%. The proportion of samples from which a MDR pathogen could be identified was significantly lower in patients with HCAP, resulting in potential sampling bias. We tried to overcome this limitation by reporting pathogen patterns according to three different denominators. In particular, the rate of 'pathogens per cases with microbial sampling', reflecting the likelihood of identifying the pathogen, allows us to estimate the true incidence more accurately. This rate did not result in different pathogen patterns. Thus, a systematic bias could only result from a general failure to investigate specific groups of patients at high risk of MDR pathogens not reflected in our general pattern. Although this cannot be categorically excluded in a potentially under-diagnosed population like those with NHAP, it is highly improbable that patients with such severe disabilities would have been subject to every treatment effort. Second, the CAPNETZ population may include too few patients with severe pneumonia. Therefore, the microbial patterns presented here must be viewed with caution when patients with HCAP are treated for severe pneumonia. Third, we did not assess aspiration, which has been described as an important aetiology in patients with NHAP and HCAP. However, the exact implications of aspiration in terms of microbial pathogens remain unresolved.^{22 32} Fourth, we did not directly measure functional status. We recorded enteral tube feeding (ETF) as a surrogate, and in fact, 78% of patients with ETF were patients with NHAP and 15.6% of patients with NHAP had ETF. Direct comparisons of mortality with other studies, however, should only be made with caution. Evidently, we ignore the external validity of these data for countries other than Germany. However, no country should regard NHAP as a condition requiring an antimicrobial treatment different from CAP prior to clear evidence that an observed excess mortality is actually related to treatment failures in the presence of potential MDR pathogens. As a note of caution, nursing homes that have patients with NHAP should invariably be regarded individually for their potential to carry a risk for the MDR pathogens.

In conclusion, the high excess mortality in our population could not be attributed to a microbial pattern different from that of CAP (including an increased incidence of potential MDR

pathogens) but is likely to be a result of comorbidity and management decisions as a result of pneumonia being regarded as a terminal event related to advanced age and poor functional status. The main challenges in the treatment of patients with NHAP include a careful assessment of individual risk factors for specific pathogens and a careful continuous estimation of prognosis and patients' preferences to set appropriate treatment aims initially and during the course of the disease.

Acknowledgements We thank Dr Mark Woodhead for his help in editing the manuscript.

Funding Bundesministerium für Bildung und Forschung (BMBF).

Competing interests None.

Ethics approval Central and local ethical committees (Ulm and local CAPNETZ centres).

Contributors All authors contributed to the manuscript. Santiago Ewig was leader of a local centre (Bonn, Bochum), analysed the data and revised the manuscript. Benjamin Klapdor analysed the data and wrote the manuscript. Mathias Pletz analysed the data. Gernot Rohde was leader of a local centre (Bochum) and analysed the data. Hartmut Schütte analysed the data. Tom Schaberg was leader of a local centre (Rotenburg) and analysed the data. Torsten Bauer was leader of a local centre (Berlin) and analysed the data. Tobias Welte is head of CAPNETZ, was leader of a local centre (Hannover), and analysed the data.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

1. Ewig S, Birkner N, Strauss R, *et al*. New perspectives on community-acquired pneumonia in 388406 patients. Results from a nationwide mandatory performance measurement programme in healthcare quality. *Thorax* 2009;**64**:1062–9.
2. Kaplan V, Angus DC, Griffin MF, *et al*. Hospitalized community-acquired pneumonia in the elderly: age- and sex-related patterns of care and outcome in the United States. *Am J Respir Crit Care Med* 2002;**165**:766–72.
3. Venkatesan P, Gladman J, Macfarlane JT, *et al*. A hospital study of community acquired pneumonia in the elderly. *Thorax* 1990;**45**:254–9.
4. Carr B, Walsh JB, Coakley D, *et al*. Prospective hospital study of community acquired lower respiratory tract infection in the elderly. *Respir Med* 1991;**85**:185–7.
5. Riquelme R, Torres A, El-Ebiary M, *et al*. Community-acquired pneumonia in the elderly: a multivariate analysis of risk and prognostic factors. *Am J Respir Crit Care Med* 1996;**154**:1450–5.
6. Riquelme R, Torres A, el-Ebiary M, *et al*. Community-acquired pneumonia in the elderly. Clinical and nutritional aspects. *Am J Respir Crit Care Med* 1997;**156**:1908–14.
7. Lieberman D, Lieberman D, Schlaeffer F, *et al*. Community-acquired pneumonia in old age: a prospective study of 91 patients admitted from home. *Age Ageing* 1997;**26**:69–75.
8. Marrie TJ. Community-acquired pneumonia in the elderly. *Clin Infect Dis* 2000;**31**:1066–78.
9. Fernández-Sabé N, Carratalà J, Rosón B, *et al*. Community-acquired pneumonia in very elderly patients: causative organisms, clinical characteristics, and outcomes. *Medicine* 2003;**82**:159–69.
10. Marrie TJ, Durant H, Kwan C. Nursing home-acquired pneumonia. A case-control study. *J Am Geriatr Soc* 1986;**34**:697–702.
11. Lim WS, Macfarlane JT. A prospective comparison of nursing home acquired pneumonia with community acquired pneumonia. *Eur Respir J* 2001;**18**:362–8.
12. Polverino E, Dambrava P, Cillóniz C, *et al*. Nursing home-acquired pneumonia: a 10 year single-centre experience. *Thorax* 2010;**65**:354–9.
13. Kollef MH, Shorr A, Tabak YP, *et al*. Epidemiology and outcomes of health-care-associated pneumonia: results from a large US database of culture-positive pneumonia. *Chest* 2005;**128**:3854–62.
14. American Thoracic Society, Infectious Diseases Society of America. Guidelines for the management of adults with hospital-acquired, ventilator-associated, and healthcare-associated pneumonia. *Am J Respir Crit Care Med* 2005;**171**:388–416.
15. Arancibia F, Bauer TT, Ewig S, *et al*. Community-acquired pneumonia due to gram-negative bacteria and *Pseudomonas aeruginosa*: incidence, risk, and prognosis. *Arch Intern Med* 2002;**162**:1849–58.
16. Ewig S, Welte T, Chastre J, *et al*. Rethinking the concepts of community-acquired and health-care-associated pneumonia. *Lancet Infect Dis* 2010;**10**:279–87.
17. Klapdor B, Ewig S, Pletz MW, *et al*; and the CAPNETZ study group. Community-acquired pneumonia in the younger is an entity of its own. 2011; (submitted).
18. Welte T, Suttrop N, Marre R. CAPNETZ-community-acquired pneumonia competence network. *Infection* 2004;**32**:234–8.
19. von Baum H, Welte T, Marre R, *et al*. *Mycoplasma pneumoniae* pneumonia revisited within the German Competence Network for Community-acquired pneumonia (CAPNETZ). *BMC Infect Dis* 2009;**9**:62.

20. **Mauch H**, Lütticken R, Gatermann S, eds. *MiQ 7 und 8. Infektionen der tiefen Atemwege. Teil I und II. Qualitätsstandards in der mikrobiologisch-infektiologischen Diagnostik. [Infection of the Deep Airways. Part I and II. Quality Standards in the Microbiological Diagnosis of Infectious Diseases]*. Jena: Gustav-Fischer Verlag, 1999.
21. **Kothe H**, Bauer T, Marre R, *et al*; Competence Network for Community-Acquired Pneumonia study group. Outcome of community-acquired pneumonia: influence of age, residence status and antimicrobial treatment. *Eur Respir J* 2008;**32**:139–46.
22. **El Solh AA**, Pietrantonio C, Bhat A, *et al*. Indicators of potentially drug-resistant bacteria in severe nursing home-acquired pneumonia. *Clin Infect Dis* 2004;**39**:474–80.
23. **Rello J**, Ausina V, Ricart M, *et al*. Nosocomial pneumonia in critically ill comatose patients: need for a differential therapeutic approach. *Eur Respir J* 1992;**5**:1249–53.
24. **Ewig S**, Torres A, El-Ebiary M, *et al*. Bacterial colonization patterns in mechanically ventilated patients with traumatic and medical head injury. Incidence, risk factors, and association with ventilator-associated pneumonia. *Am J Respir Crit Care Med* 1999;**159**:188–98.
25. **Guertler C**, Wirz B, Christ-Crain M, *et al*. Inflammatory responses predict long-term mortality risk in community-acquired pneumonia. *Eur Respir J* 2011;**37**:1439–46.
26. **Garcia-Vidal C**, Viasus D, Roset A, *et al*. Low incidence of multidrug-resistant organisms in patients with healthcare-associated pneumonia requiring hospitalization. *Clin Microbiol Infect* 2011;**17**:1659–65.
27. **Chalmers JD**, Taylor JK, Singanayagam A, *et al*. Epidemiology, antibiotic therapy, and clinical outcomes in health care-associated pneumonia: a UK cohort study. *Clin Infect Dis* 2011;**53**:107–13.
28. **Marrie TJ**, Blanchard W. A comparison of nursing home-acquired pneumonia patients with patients with community-acquired pneumonia and nursing home patients without pneumonia. *J Am Geriatr Soc* 1997;**45**:50–5.
29. **El Solh AA**, Alhajjhasan A, Ramadan FH, *et al*. A comparative study of community- and nursing home-acquired empyema thoracis. *J Am Geriatr Soc* 2007;**55**:1847–52.
30. **El Solh AA**, Akinnusi ME, Alfarah Z, *et al*. Effect of antibiotic guidelines on outcomes of hospitalized patients with nursing home-acquired pneumonia. *J Am Geriatr Soc* 2009;**57**:1030–5.
31. **Attridge RT**, Frei CR, Restrepo MI, *et al*. Guideline-concordant therapy and outcomes in healthcare-associated pneumonia. *Eur Respir J* 2011;**38**:878–87.
32. **Carratalá J**, Mykietiuk A, Fernández-Sabé N, *et al*. Health care-associated pneumonia requiring hospital admission: epidemiology, antibiotic therapy, and clinical outcomes. *Arch Intern Med* 2007;**167**:1393–9.

Journal club

Improved survival in cystic fibrosis patients with severely impaired lung function

A forced expiratory volume in one second (FEV₁) less than 30% predicted has been accepted as the threshold at which 50% of patients with cystic fibrosis (CF) survive 2 years or less. However, this estimate, made in the early 1990s, does not take into account recent developments in treatment. This cohort study aimed to re-evaluate the survival of CF patients with severely impaired lung function.

Two hundred and seventy-six CF patients whose FEV₁ was first observed to be less than 30% predicted between 1990 and 2003 were included in the cohort. The patients were followed up in 2-year subcohorts until 2007 and their survival was assessed. The authors showed an important improvement in the average survival of CF patients with severely impaired lung function. Median survival for patients who entered the cohort most recently (2002–2003) was 5.3 years, more than four times that for those who entered the study in the early 1990s, when median survival was 1.2 years. The authors observed a clear stepwise improvement in survival from 1994 to 1997. This was concurrent with the introduction of nebulised recombinant human DNase. A steady improvement in nutritional status also occurred in the time period studied, and an increased risk of death was associated with a body mass index below 19 kg/m².

The survival of patients with CF and an FEV₁ less than 30% predicted has improved markedly over the last two decades, with a median predicted survival of 5.3 years.

► **George PM**, Banya W, Pareek N, *et al*. Improved survival at low lung function in cystic fibrosis: cohort study from 1990 to 2007. *BMJ* 2011;**342**:1008.

Vishal Narwani

Correspondence to Vishal Narwani, Medical student, Royal Free Hospital, Pond Street, London NW3 2QG, UK; vishal.narwani.10@ucl.ac.uk

Published Online First 4 May 2011

Thorax 2012;**67**:138. doi:10.1136/thoraxjnl-2011-200357